India, Jan. 28 -- Drug major Johnson & Johnson (JNJ) announced Tuesday that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) -based quadruplet regimen has received the U.S. Food and Drug Administration approval to treat adult patients with newly diagnosed multiple myeloma or NDMM, who are ineligible for autologous stem cell transplant (ASCT).
DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone or D-VRd has received the approval. The company noted that D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplant eligibility.
Multiple myeloma, a blood cancer that affects a type of white blood cell cal...